CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis.

Zeng, Ni; Han, Jiaqi; Liu, Zijian; He, Jinlan; Tian, Kun; Chen, Nianyong

Zeng, Ni; Han, Jiaqi; Liu, Zijian; He, Jinlan; Tian, Kun; Chen, Nianyong.

Afiliação

Zeng N; Department of Head and Neck Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Han J; Department of Radiation Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Liu Z; Department of Head and Neck Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
He J; Department of Radiation Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Tian K; Department of Head and Neck Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Chen N; Department of Radiation Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.

Cancers (Basel) ; 15(13)2023 Jun 28.

Article em En | MEDLINE | ID: mdl-37444496

Palavras-chave

CDK4/6 inhibitors; HR+/HER2− advanced or metastatic breast cancer; abemaciclib; anastrozole; cost-effectiveness; letrozole; network meta-analysis; palbociclib; ribociclib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Health_economic_evaluation / Systematic_reviews Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google